Skip to main content

OUP Management Co., LLC

13F filer · CIK 0001880124
Last filed Nov 9, 2023
Inactive · not filing 13F
13F portfolio value$44.5MU.S. long equity reported on 13F
Positions90 new · 1 closed
Net flow last quarter-$12.5MBuys minus sells
Top 10 positions weight83.9%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q3 2023Reported Nov 9, 20239 positions
CNTACentessa Pharmaceuticals PLC$19M42.74%3.01%Not reportedQ4 2021
AVTEJade Biosciences, Inc.$8.19M18.43%Not reportedNot reportedQ4 2021
PMVPPMV Pharmaceuticals, Inc.$6.07M13.66%1.93%Not reportedQ4 2021
GRPHGraphite Corp.$1.01M2.27%0.20%Not reportedQ4 2021
RNACCartesian Therapeutics, Inc.$914K2.06%0.56%Not reportedQ4 2021
VORVor Biopharma Inc.$794K1.79%0.55%Not reportedQ4 2021
EFTReFFECTOR Therapeutics, Inc.$615K1.38%1.64%Not reportedQ4 2021
DTILPrecision Biosciences Inc$384K0.86%0.97%Not reportedQ4 2021
SPROSpero Therapeutics, Inc.$301K0.68%0.47%Not reportedQ4 2021
Q2 2023Reported Aug 7, 202310 positions
CNTACentessa Pharmaceuticals PLC$18.2M31.01%3.08%Not reportedQ4 2021
DICEDice Therapeutics, Inc.$12.5M21.26%0.56%Not reportedQ4 2021
AVTEJade Biosciences, Inc.$10.4M17.66%Not reportedNot reportedQ4 2021
PMVPPMV Pharmaceuticals, Inc.$6.19M10.56%2.14%Not reportedQ4 2021
VORVor Biopharma Inc.$1.16M1.97%0.56%Not reportedQ4 2021
GRPHGraphite Corp.$1.06M1.80%0.20%Not reportedQ4 2021
RNACCartesian Therapeutics, Inc.$966K1.65%0.56%Not reportedQ4 2021
EFTReFFECTOR Therapeutics, Inc.$852K1.45%1.67%Not reportedQ4 2021
DTILPrecision Biosciences Inc$591K1.01%0.98%Not reportedQ4 2021
SPROSpero Therapeutics, Inc.$361K0.62%0.47%Not reportedQ4 2021
Q1 2023Reported Apr 24, 202312 positions
AVTEJade Biosciences, Inc.$12.2M24.30%Not reportedNot reportedQ4 2021
CNTACentessa Pharmaceuticals PLC$11.3M22.57%3.09%Not reportedQ4 2021
DICEDice Therapeutics, Inc.$7.69M15.34%0.56%Not reportedQ4 2021
PMVPPMV Pharmaceuticals, Inc.$4.72M9.42%2.16%Not reportedQ4 2021
IONQIonQ, Inc.$2.4M4.78%0.19%-66.9%Q4 2021
VORVor Biopharma Inc.$2.02M4.02%0.56%Not reportedQ4 2021
PRMEPrime Medicine, Inc.$1.49M2.98%0.12%Not reportedQ4 2022
RNACCartesian Therapeutics, Inc.$1.2M2.39%0.56%Not reportedQ4 2021
GRPHGraphite Corp.$995K1.99%0.20%Not reportedQ4 2021
DTILPrecision Biosciences Inc$847K1.69%1.00%Not reportedQ4 2021
EFTReFFECTOR Therapeutics, Inc.$362K0.72%2.44%Not reportedQ4 2021
SPROSpero Therapeutics, Inc.$361K0.72%0.47%Not reportedQ4 2021
Q4 2022Reported Feb 2, 202312 positions
AVTEJade Biosciences, Inc.$17.7M28.88%Not reportedNot reportedQ4 2021
CNTACentessa Pharmaceuticals PLC$9.11M14.87%3.10%Not reportedQ4 2021
PMVPPMV Pharmaceuticals, Inc.$8.61M14.05%2.16%Not reportedQ4 2021
DICEDice Therapeutics, Inc.$8.37M13.67%0.56%-50.0%Q4 2021
IONQIonQ, Inc.$4.06M6.63%0.59%Not reportedQ4 2021
VORVor Biopharma Inc.$2.49M4.07%0.57%Not reportedQ4 2021
PRMEPrime Medicine, Inc.$2.25M3.68%0.12%NewQ4 2022
GRPHGraphite Corp.$1.35M2.20%0.20%Not reportedQ4 2021
DTILPrecision Biosciences Inc$1.34M2.18%30.39%Not reportedQ4 2021
RNACCartesian Therapeutics, Inc.$975K1.59%0.56%Not reportedQ4 2021
EFTReFFECTOR Therapeutics, Inc.$439K0.72%61.51%Not reportedQ4 2021
SPROSpero Therapeutics, Inc.$431K0.70%0.47%Not reportedQ4 2021
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.